300406.SZ SHZ
Beijing Strong Biotechnologies, Inc.
1W: +1.3%
1M: +3.2%
3M: +6.5%
YTD: -10.4%
1Y: -17.1%
3Y: -39.8%
5Y: -29.5%
¥11.94 ($1.78)
+0.17 (+1.44%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.7B
-4.7% ▼
5Y CAGR: +14.6%
Gross Profit
$1.3B
+0.0% ▲
5Y CAGR: +17.6%
Operating Income
$624M
+5.1% ▲
5Y CAGR: +10.6%
Net Income
$533M
+1.7% ▲
5Y CAGR: +9.9%
EPS (Diluted)
$0.90
+2.3% ▲
5Y CAGR: +6.4%
EBITDA
$701M
+6.5% ▲
5Y CAGR: +12.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $848M | $1.6B | $1.5B | $1.7B | $1.7B |
| YoY Growth | +0.9% | +88.6% | -5.5% | +15.3% | -4.7% |
| Cost of Revenue | $328M | $449M | $384M | $445M | $362M |
| Gross Profit | $520M | $1.2B | $1.1B | $1.3B | $1.3B |
| Gross Margin | 61.3% | 72.0% | 74.6% | 74.4% | 78.2% |
| R&D Expenses | $79M | $127M | $137M | $163M | $189M |
| SG&A Expenses | $245M | $444M | $457M | $491M | $458M |
| Operating Expenses | $367M | $615M | $671M | $703M | $673M |
| Operating Income | $153M | $536M | $455M | $594M | $624M |
| Operating Margin | 18.0% | 33.5% | 30.1% | 34.1% | 37.6% |
| Interest Expense | $10M | $22M | $53M | $47M | $48M |
| Income Before Tax | $137M | $537M | $449M | $594M | $621M |
| Tax Expense | $15M | $67M | $55M | $71M | $90M |
| Net Income | $112M | $406M | $389M | $524M | $533M |
| Net Margin | 13.2% | 25.4% | 25.8% | 30.1% | 32.1% |
| EPS (Diluted) | $0.21 | $0.69 | $0.66 | $0.88 | $0.90 |
| EBITDA | $196M | $591M | $554M | $658M | $701M |
| Shares Outstanding | 535M | 588M | 589M | 595M | 592M |